- Home
- HOWL
as 05-17-2024 4:00pm EST
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 212.1M | IPO Year: | 2021 |
| Target Price: | $10.86 | AVG Volume (30 days): | 182.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.57 - $8.19 | Next Earning Date: | 05-03-2024 |
| Revenue: | $16,221,000 | Revenue Growth: | -22.26% |
| Revenue Growth (this year): | -70.18% | Revenue Growth (next year): | 165.38% |
Share on Social Networks:
Latest Werewolf Therapeutics Inc. News
HOWL Breaking Stock News: Dive into HOWL Ticker-Specific Updates for Smart Investing
GlobeNewswire
17 days ago
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
25 days ago
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
a month ago
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
Zacks
a month ago
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
GlobeNewswire
a month ago
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
GlobeNewswire
a month ago
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
Zacks
2 months ago
How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%
Simply Wall St.
2 months ago